Mitem® is a cytostatic injectable mitomycin product used in the treatment of a range of cancers.
Most notably, Mitem® is given intravesically (in the bladder) for the treatment of non-muscle invasive bladder cancer. Mitomycin is the gold standard in this treatment of bladder cancer.
Directly after a minimally invasive procedure resecting the tumour out of the bladder wall, Mitem is instilled intravesically as a prophylactic treatment, followed by regular instillations for up to 12 months after the first treatment. According to the European Urology guidelines this treatment clearly reduces the chances of recurrence of the bladder cancer.
SEP acquired the product in December 2010 and took over the German distribution shortly thereafter. The product was approved throughout much of the EU in early 2013 and company plans to launch the product in other European countries once marketing authorisations are granted.
More information can be found (in German) at: www.mitem.de